Fig. 2: Mechanisms of resistance to immune checkpoint inhibitors in hepatocellular carcinoma. | npj Gut and Liver

Fig. 2: Mechanisms of resistance to immune checkpoint inhibitors in hepatocellular carcinoma.

From: Improving immunotherapy for the treatment of hepatocellular carcinoma: learning from patients and preclinical models

Fig. 2

Illustration of the various mechanisms through which HCC cells may develop resistance to immune checkpoint inhibitors (ICIs). 1) Mutation or altered expression of antigen-presenting molecules on tumor cells leading to reduced T-cell recognition. 2) Impaired antigen presentation. 3) Alterations in the tumor microenvironment, or secretion of immunosuppressive cytokines by tumor cells. 4) Impaired T-cell phenotype, or a physical barrier repressing T-cell infiltration. 5) Altered tumor recognition by T cells. 6) Recruitment of immunosuppressive macrophages, myeloid-derived suppressor cells (MDSCs), or regulatory T cells (Tregs) to the tumor microenvironment, suppressing the activation and proliferation of T cells. 7) Upregulation of alternate immune checkpoints in tumor cells, rendering standard ICIs ineffective. 8) T-cell exhaustion is characterized by the overexpression of multiple inhibitory receptors, diminishing the immune response. The figure underscores the complexity of the tumor-immune microenvironment and the multifaceted nature of immune resistance in HCC, highlighting the need for multi-targeted approaches.

Back to article page